Table 1 –

Patient cohort demographics including sequencing analysis and prior surgical or medical treatments. All treatments listed occurred prior to index CRS/ HIPEC. Successful patient-derived tumor organoid fabrication (PTO) as defined by viable controls at 10 days of culture. Tumor mutations identified utilizing FoundationOne® CDx testing.

Patient	Tumor Histologic Type & Grade	Tumor Mutation(s)	Prior Treatment(s)	Successful PTO Fabrication	Immune Component	Treatment Effect	Patient Response To Immunotherapy	Correlation?
1	High grade mucinous adenocarcinoma with signet ring cell features (HGA)	RAS	FOLFOX, FOLFIRI	No	PBMC	NR	N/A
2	High grade mucinous adenocarcinoma with signet ring cell features (HGA)	KRAS, PD-L1 ≥ 1%	Xeloda	Yes	PBMC	NR	NR (Pembrolizumab)	Yes
3	Low grade appendiceal mucinous neoplasm (LAMN)	N/A	N/A	Yes	PBMC	Nivolumab	N/A
4	High grade adenocarcinoma, non-mucinous (HGA)	N/A	FOLFOX	Yes	PBMC, LN^	Pembrolizumab*	N/A
5	High grade adenocarcinoma, non-mucinous (HGA)	PD-L1 ≥ 1%	FOLFOX	No	PBMC	NR	N/A
6	High grade mucinous adenocarcinoma with signet ring cell features (HGA)	Negative	Ileocecectomy, FOLFOX, CRS/HIPEC (MMC/Doxorubicin)	Yes	PBMC	Pembrolizumab	N/A
7	Low grade mucinous adenocarcinoma (LGA)	PD-L1 ≥ 1%	FOLFOX, CRS/HIPEC, Camptosar/Avastin	Yes	PBMC	NR	N/A
8	Low grade appendiceal mucinous neoplasm (LAMN)	N/A	N/A	Yes	PBMC	NR	N/A
9	Low grade appendiceal mucinous neoplasm (LAMN)	N/A	N/A	Yes	PBMC	NR	N/A
10	Low grade appendiceal mucinous neoplasm (LAMN)	N/A	FOLFOX	Yes	PBMC	NR	N/A
11	Low grade appendiceal mucinous neoplasm (LAMN)	N/A	CRS/HIPEC (MMC)	Yes	PBMC	NR	N/A
12	Low grade appendiceal mucinous neoplasm (LAMN)	N/A	N/A	Yes	PBMC	Pembrolizumab	N/A
13	Low grade appendiceal mucinous neoplasm (LAMN)	N/A	CRS/HIPEC (MMC)	Yes	PBMC	NR	N/A
14	Low grade appendiceal mucinous neoplasm (LAMN)	Negative	CRS, Carboplatin/Paclitaxel	No	PBMC	NR	N/A
15	High grade mucinous adenocarcinoma (HGA)	MMR proficient	CRS/HIPEC x2 (MMC & Oxaliplatin)	Yes	PBMC	NR	N/A
16	High grade mucinous adenocarcinoma (HGA)	MMR proficient, PD-L1 ≥ 1%	CRS/HIPEC (MMC), FOLFOXIRI, CRS	No	PBMC	NR	N/A
17	Low grade appendiceal mucinous neoplasm (LAMN)	KRAS, NRAS, TMB ≥ 10 Muts/Mb	Right hemicolectomy, FOLFOX, FOLFIRI	Yes	PBMC	NR	Receiving Pembrolizumab (NR)	Yes
18	Low grade appendiceal mucinous neoplasm (LAMN)	N/A	Diagnostic laparoscopy	Yes	Spleen	Pembrolizumab	N/A
19	Low grade appendiceal mucinous neoplasm (LAMN)	N/A	CRS, CRS/HIPEC (MMC), FOLFOX	No	PBMC	NR	N/A
20	High grade mucinous adenocarcinoma (HGA)	N/A	FOLFOX	No	PBMC	NR	N/A
21	Low grade appendiceal mucinous neoplasm (LAMN)	N/A	N/A	Yes	PBMC, LN^	NR	N/A
22	Low grade mucinous adenocarcinoma (LGA)	N/A	CRS, CRS/HIPEC (MMC)	No	PBMC	NR	N/A
23	Low grade appendiceal mucinous neoplasm (LAMN)	N/A	N/A	Yes	PBMC	NR	N/A
24	Low grade appendiceal mucinous neoplasm (LAMN)	N/A	N/A	Yes	PBMC	NR	N/A
25	High grade mucinous adenocarcinoma with signet ring cell features (HGA)	KRAS	Appendectomy, FOLFOX	Yes	PBMC	Nivolumab	N/A
26	High grade mucinous adenocarcinoma with signet ring cell features (HGA)	Negative	Small bowel resection, FOLFOX	Yes	PMBC	NR	N/A

RAS – Rat sarcoma oncogene; KRAS – Kirsten rat sarcoma oncogene; NRAS – neuroblastoma rat sarcoma oncogene; PD-L1 – Programmed death ligand 1; MMR – mismatch repair proteins; TMB – tumor mutational burden; CRS – cytoreductive surgery; HIPEC – heated intraperitoneal chemotherapy; FOLFOX – folinic acid, fluorouracil, oxaliplatin; FOLFIRI – folinic acid, fluorouracil, irinotecan; MMC – mitomycin C; FOLFOXIRI – folinic acid fluorouracil, oxaliplatin, irinotecan. PBMC – Peripheral blood mononuclear cells; LN – lymph node.

^{^}Immune-enhanced PTOs (iPTOs) generated separately for PBMC and LN.

^*Pembrolizumab effective under both PBMC and LN immune component conditions. N/A – information not available. NR – no treatment response. We refer to LGA and LAMN collectively as low grade appendiceal primaries (LGA).